Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Herpes simplex virus vaccine reduces HSV-1 corneal disease

July 24, 1998

BioLon receives FDA approval

July 23, 1998

FDA grants fast track status to Miravant's Purlytin

July 10, 1998

Allergan signs collaborative agreement with Santen for brimonidine

July 10, 1998

Clinical update on Advanced Corneal Systems' Vitrase

July 6, 1998

Gene linked to inherited glaucoma

July 6, 1998

Miravant and Pharmacia & Upjohn amend Purlytin agreements

June 15, 1998

Asahi Glass, Santen develop ophthalmic agents with good safety

June 12, 1998

Latanoprost compared to unoprostone in monkeys with glaucoma

June 10, 1998

CAT's monoclonal antibody progresses in ophthalmic clinical trials

June 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...